Kristina M. Deligiannidis, MD; Samantha Meltzer-Brody, MD, MPH; Handan Gunduz-Bruce, MD, MBA; et al.
has active quiz
JAMA Psychiatry. 2021;78(9):951-959. doi:10.1001/jamapsychiatry.2021.1559
This randomized clinical trial assesses the efficacy and safety of zuranolone, a neuroactive steroid γ-aminobutyric acid receptor–positive allosteric modulator, in individuals with postpartum depression.
Michael J. Constantino, PhD; James F. Boswell, PhD; Alice E. Coyne, MS; et al.
JAMA Psychiatry. 2021;78(9):960-969. doi:10.1001/jamapsychiatry.2021.1221
This randomized clinical trial investigates the effect of measurement-based matching vs case assignment as usual on psychotherapy outcomes.
Gonzalo Salazar de Pablo, MD; Joaquim Radua, MD, PhD; Joana Pereira, MD; et al.
JAMA Psychiatry. 2021;78(9):970-978. doi:10.1001/jamapsychiatry.2021.0830
This meta-analysis examines the current consistency and magnitude of transition risk to psychosis in individuals at clinical high risk.
Thomas Santo Jr, MPH; Brodie Clark, BPsych; Matt Hickman, PhD; et al.
JAMA Psychiatry. 2021;78(9):979-993. doi:10.1001/jamapsychiatry.2021.0976
This systematic review and meta-analysis investigates the association of opioid agonist treatment with risk of overall and cause-specific mortality among people with opioid dependence.
Sidhant Chopra, BSc; Shona M. Francey, PhD; Brian O’Donoghue, MD, PhD; et al.
JAMA Psychiatry. 2021;78(9):994-1004. doi:10.1001/jamapsychiatry.2021.1422
This secondary analysis of a randomized clinical trial investigates differential patterns of brain connectivity in antipsychotic-treated and antipsychotic-naive patients with psychosis and how these patterns change over time.
Negar Fani, PhD; Sierra E. Carter, PhD; Nathaniel G. Harnett, PhD; et al.
JAMA Psychiatry. 2021;78(9):1005-1012. doi:10.1001/jamapsychiatry.2021.1480
This cross-sectional study examines associations of discriminatory experiences with brainwide response to threat-relevant cues in Black women in the US exposed to trauma as they engage in an attentionally demanding task.
Carsten Hjorthøj, PhD; Christine Merrild Posselt, MSc; Merete Nordentoft, DrMedSc
JAMA Psychiatry. 2021;78(9):1013-1019. doi:10.1001/jamapsychiatry.2021.1471
This nationwide, register-based historical cohort study assesses whether the population-attributable risk fraction (PARF) for cannabis use disorder in schizophrenia has increased over time in Denmark.
Audio Author Interview:
Development Over Time of the PARF for Cannabis Use Disorder in Schizophrenia in Denmark
Weiqiu Cheng, PhD; Oleksandr Frei, PhD; Dennis van der Meer, PhD; et al.
JAMA Psychiatry. 2021;78(9):1020-1030. doi:10.1001/jamapsychiatry.2021.1435
This genetic association study investigates the extent of shared genetic architecture between schizophrenia and brain cortical surface area and thickness.
Matthew D. Albaugh, PhD; Jonatan Ottino-Gonzalez, PhD; Amanda Sidwell, BS; et al.
JAMA Psychiatry. 2021;78(9):1031-1040. doi:10.1001/jamapsychiatry.2021.1258
This cohort study examines the degree to which magnetic resonance imaging–assessed cerebral cortical thickness development is associated with cannabis use in a longitudinal sample of adolescents.
Audio Author Interview:
Association of Cannabis Use During Adolescence With Neurodevelopment